We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ip Group Plc | IPO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.60 | 3.49% | 47.50 | 16:35:11 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 48.00 | 46.25 | 48.05 | 47.50 | 45.90 |
| Industry Sector |
|---|
| GENERAL FINANCIAL |
| Top Posts |
|---|
Posted at 05/4/2024 16:57 by brucie5 Yes, aware of the technical breakthrough at FLF, though I'm not yet convinced that this brings it much closer to being a 'business' so much as an important contribution to experimental advances in the science of NF. I expect this will be the eventual value of it an acquirer.While I get your point about buybacks, it would be nice for shareholders to be rewarded to some degree in some way! How about some special dividends based on profits of any next sales? Normally, investors are agreeable to taking share price growth in lieu of income, but as we all know, that advantage hardly applies here! One for believers only! In the meantime ONT travels forever southerly to where I expect it to fetch up at £1 quite shortly. |
Posted at 12/10/2023 10:33 by bamboo2 Hard to see a cost/benefit justification for this...FOR RELEASE ON 12 October 2023 IP Group - Webinar on ESG & Impact IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it will hold a webinar on ESG and impact entitled "ESG Forward - our approach to impact" on Thursday November 16 2023 . Our Head of ESG, Bran Pathman ban, will be joined by our CEO Greg Smith and CFOO David Baynes to discuss the Group's approach to ESG and impact, as well as the broader challenges of providing a meaningful narrative around impact. We're delighted to be joined by special guest Alex Edmans, Pro fessor of Finance at London Business School. Alex has a PhD from MIT as a Fulbright Scholar and was previously a tenured professor at Wharton and an investment banker at Morgan Stanley. He serves as non-executive director of the Investor Forum, on the World Economic Forum's Global Future Council on Responsible Investing, and on Royal London Asset Management's Responsible Investment Advisory Committee. Further details of the event, which will start at 9am, and how to register can be found on t he events section of our website : hxxps://www.ipgroupp The update will be hosted live via the Investor Meet Company platform. Questions can be submitted in advance of the event via the Investor Meet Company Platform up to 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: hxxps://www.investor No material new information will be released by the Company during the presentation. |
Posted at 22/4/2023 18:25 by bamboo2 FOR RELEASE ON 20 April 2023IP Group - 2022 Annual Report; Notice of Annual General Meeting ("AGM") IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it has published its Annual Report and Accounts for the year ended 31 December 2022. In compliance with Listing Rule 9.6.3, a copy of the following documents will shortly be available for inspection at www.fca.org.uk/marke - Annual Report and Accounts for the year ended 31 December 2022 ("2022 ARA"); and - Notice of 2023 Annual General Meeting ("2023 AGM Notice"). Printed copies of the 2022 ARA and the 2023 AGM Notice, together with the Form of Proxy for use in connection with the 2023 AGM, have been posted to shareholders who have requested hard copies. An electronic copy of the 2022 ARA is available on the Investor Relations section of the IP Group website at www.ipgroupplc.com/i The 2023 AGM will be held at 11.00am on 15 June 2023 at the Company's offices at 3 Pancras Square, King's Cross, London, N1C 4AG, as further set out in the 2023 AGM Notice. To ensure that shareholders can also follow the proceedings of the AGM virtually, the Company will provide access online via the Investor Meet Company platform. However, please note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible, as further detailed in the 2023 AGM Notice. The Company will also hold an investor event immediately before the AGM at which an update on the Group will be provided and shareholders will be able to ask questions of the Board. Any shareholder attending the AGM in person will be able to attend the shareholder event (and vice versa). The shareholder event will take place from 9.30am-10.30am (with refreshments available from 9.00am) and will also be streamed live to those who wish to attend virtually. Whilst live questions will be accepted on the day, in order to facilitate the smooth running of the shareholder event and AGM, shareholders are encouraged to submit any questions for the Board to consider via the Investor Meet Company Platform up until 9am the day before the AGM. Shareholders can also submit questions in advance by email to cosec@ipgroupplc.com up to 48 hours prior to the time of the AGM. Shareholders that wish to attend the shareholder event and AGM remotely should register in advance by using the following link: . |
Posted at 21/2/2023 22:24 by bamboo2 21 Feb 2023Largest funding round in UK Quantum Computing Quantum Motion, a UK-based quantum computing scale-up founded by Professor John Morton, UCL, and Professor Simon Benjamin, Oxford University, has raised over £42 million in equity funding from some of the world’s leading quantum and technology investors. The oversubscribed round is led by Bosch Ventures (RBVC) and joined by Porsche Automobil Holding SE (Porsche SE) and British Patient Capital. All existing investors from earlier rounds (Oxford Science Enterprises, Inkef, Parkwalk Advisors, Octopus Ventures, IP Group and NSSIF) are again participating. This is one of the most significant raises in UK quantum computing and allows Quantum Motion to accelerate its development of silicon quantum processors by developing deeper ties with its manufacturing partners and trebling the size of its central London headquarters. Quantum computers offer an opportunity for transformative computing power with the potential to disrupt sectors ranging from energy and pharmaceuticals to finance and logistics. Quantum Motion’s vision is to develop scalable quantum computers by harnessing highly advanced silicon transistor manufacturing processes. Over the last two years the company has made a series of peer-reviewed and record-breaking achievements that underline how silicon could be the fastest, most cost-effective and scalable way of producing the millions of qubits that are needed to create fully-functional, fault tolerant quantum computers. Quantum Motion’s latest funding round brings the total raised to £62 million. The company has previously raised over £20m in equity and grant funding from the UK and EU and existing investors which have supported the company through its early-stage work and growth, enabling it to hit a sequence of milestones that demonstrate a clear path towards building quantum computers. It has designed and validated integrated circuits capable of generating, routing and processing signals at deep cryogenic temperatures, operating down to a few tenths of a degree above absolute zero. Recent demonstrations such as the mass characterisation of thousands of multiplexed quantum dots fabricated in a tier one foundry have further underlined the company’s advantage. James Palles-Dimmock, CEO of Quantum Motion, said, “The support of leading technology investors enables us to realise our vision of a quantum computer built using standard foundry processes. This support, along with the continuing UK national quantum programme and European initiatives, provides a step-change in our capabilities. We have assembled a world leading team and with the funding and support in place, we are ready to scale and deliver on our vision.” Investor quotes Ingo Ramesohl, Managing Director, Bosch Ventures, said, “CMOS based quantum computing leverages on today’s sophisticated chip manufacturing processes and fabs. Quantum Motion has demonstrated that it can take quantum theory out of a lab into the real world to create a scalable path to a quantum future. We’re excited to join the company and break new ground in the years to come.” Lutz Meschke, board member at Porsche SE, said, “The approach of Quantum Motion has tremendous potential with respect to the cost-effective scalability and wide-spread deployment of quantum computing in many industries. We are looking forward to supporting one of the world’s leading teams in the development and industrialisation of this technology.” Catherine Lewis La Torre, CEO of British Patient Capital, said: “Quantum Motion blends sector expertise with a unique offering that is pushing the boundaries of quantum computing. Quantum computers will play an essential role in solving challenges that are far beyond the computational capabilities of today’s super computers. We are delighted to be investing in this UK deeptech leader via Future Fund: Breakthrough as the business continues to develop cutting-edge technologies.” Sam Harman, Investor Director, Oxford Science Enterprises, said, “Quantum Motion is a powerhouse of technical and commercial talent, which has put the UK at the forefront of silicon quantum development globally. We’re proud to have been part of the journey since the beginning, and thrilled to continue our support alongside a strong syndicate of new investors, as the team takes the next step towards realising their end vision.” Neil Cameron, Investor Director at Parkwalk, said, “Parkwalk, a founder investor in the UK quantum industry, is delighted to follow its investment in Quantum Motion. The team has consistently achieved and even surpassed the planned technical milestones and we are confident that their ground breaking work will only accelerate with this significant increase in funding. We believe quantum computing will transform many industries, and it is essential that the UK is at the forefront of this revolution.” Industry luminary and Chairman of the board Alberto Sangiovanni-Vincente ENDS About Quantum Motion Quantum Motion is developing a revolutionary technology platform; not just a qubit, but a scalable array of qubits based on the ubiquitous silicon technology already used to manufacture the chips in smartphones and computers. The company is developing fault tolerant quantum computing architectures that are compatible with CMOS processes. Fault tolerant quantum processors will support the most powerful quantum algorithms, targeting solutions to currently intractable problems in fields as diverse as chemistry, materials science, medicine and artificial intelligence. The company employs 40 people, comprising specialists in quantum theory, engineering and software. www.quantummotion.te |
Posted at 16/2/2023 15:28 by bamboo2 London, 16 February 2023Kiko Ventures joins Cleantech for UK coalition to supercharge UK cleantech, supported by Breakthrough Energy On 15th February, Kiko Ventures joined other leading cleantech accelerators and investors in the UK, with combined funds of over £6 billion, founding a coalition to help inform and shape a new initiative, called Cleantech for UK. This initiative, which aims to pave the way for a new generation of global cleantech champions in the UK, is supported by Breakthrough Energy and organised by Cleantech Group. The participants were joined by Bill Gates and UK PM Rishi Sunak for the launch event, where they discussed how to create the next generation of global cleantech champions in the UK. “The UK has all the ingredients to become a major player in the global push to build our net-zero emissions future, including world-class research facilities and forward-looking investors. I am confident that the Cleantech for UK coalition will become a key bridge between cleantech investors, innovators and policy makers,” said Ann Mettler, Vice President for Europe at Breakthrough Energy. UK cleantech venture capital investment was £3.2 billion in 2022, equalling the record-breaking amounts of 2021. This is especially remarkable in a cooling global venture capital climate. But as other countries enact increasingly ambitious climate packages such as the Inflation Reduction Act (IRA) in the USA, and the Net Zero Industry Act in the EU, the UK must go further and faster to maintain competitiveness. The UK would have to spend a total of £36bn to reach the GDP equivalent of the IRA. “As the most active cleantech VC in the UK for the last decade, we know how much innovation there is in Britain for climate solutions. However, big cleantech innovations need all stakeholders to work together to make them a reality. Cleantech for UK will help set the agenda and make the connections needed so that cleantech innovation can thrive.”, said Arne Morteani, Founding Partner at Kiko Ventures. The Cleantech for UK coalition’s objective is to supercharge UK cleantech innovation. The UK is home to excellent scientific research and a thriving innovation scene. But this world-leading capability is not consistently translated into world-leading cleantech scale-ups. “To secure the enormous benefits on offer to those brave enough to lead the transformation of our industrialised economies to cleaner, decarbonised and resource-efficient versions of themselves will require innovation in all facets,” said Richard Youngman, CEO, Cleantech Group. “Yes, technological, but equally in financial instruments and in policy-making. I believe a period of intense dialogue, experimentation and hyper-collaboration is needed for the UK to deliver on its net zero goals, its economic growth ambitions, and its national security.” Founding members of the coalition are: Imperial College London’s cleantech accelerator Undaunted, Clean Growth Fund (cleantech venture capital investor), Kiko Ventures (cleantech venture capital investor), Breakthrough Energy Ventures (cleantech venture capital investor), Just Climate (climate-led investor), Legal & General Capital (alternative asset platform). The work of the coalition will be facilitated by Cleantech for UK. Cleantech for UK is a new initiative to establish a dialogue between the UK’s policy-making community and those living the reality of creating, incubating, investing in and scaling cleantech companies. Cleantech for UK is powered by Cleantech Group and supported by Breakthrough Energy. Similar programmes in continental Europe include Cleantech for Europe, Cleantech for France, Tech for Net Zero Allianz, Cleantech for Nordics and Cleantech for Baltics. |
Posted at 12/1/2023 23:03 by bamboo2 Activity in the self-driving car industry, frenetic for years, has somewhat stalled in more recent times, but a handful of the most promising companies are continuing to see their businesses grow and attract investment in the process. In one of the more recent developments, Oxbotica, a startup out of England that develops software to power autonomous vehicles, has closed a Series C round of $140 million, money that it will be using to continue building out services for existing clients and to drum up new business in that wake.The size of the round is big by any terms, but it’s a signal of how AI startups especially continue to fare well at the moment. It also shows the kinds of companies that are working with, and looking to back, startups breaking new ground in the space of autonomous driving. The basic model for Oxbotica — eight years old and based out of Oxford, England — is B2B: It sells and customizes its autonomous software, which it dubs “Universal Autonomy,” for a range of enterprise customers. Its premise is that its flexible technology can power whatever it is that a customer needs: navigation, perception, user interfaces, fleet management or other features needed to run self-driving vehicles in multiple environments, regardless of the hardware being used and in integration with whatever other software its customers are using. Underscoring its traction with that premise, this latest funding is coming from a mix of investors that include some of those strategic backers and customers. Japan’s Aioi Nissay Dowa Insurance Co., Ltd., and ENEOS Innovation Partners, the corporate VC of the mining conglomerate Eneos, are among its new investors; previous backers in this round include BGF, safety equipment group Halma, hospitality and recreation investor Hostplus, climate fund Kiko Ventures (IP Group), the online shopping company Ocado Group, internet giant Tencent, Venture Science and automotive component maker ZF. Several of these companies also invested in Oxbotica’s last round, a Series B in January 2021 of $47 million. This round brings the total raised by Oxbotica to $225 million. The startup is not disclosing its valuation, but Paul Newman, the company’s CTO and co-founder, noted that the fact that it was one of the autonomous startups that’s raising big right now, and the current appetite for artificial intelligence startups that are building applications around their innovations, have contributed to a healthy number. “You should take it to be in a space that investors are valuing greatly,” he said. At a moment when businesses, consumers, investors and startups themselves are reassessing things like self-driving technology through a more pragmatic lens, asking questions about unit economics and commercial and technical viability, Oxbotica, he said, has emerged as a leader in “the application of autonomy where the world needs it.” That translated also into much shorter conversations with investors, the kind that are generally not happening across other sectors in tech. “It didn’t take that much time at all to show you can solve what is really needed versus what is not a problem at all,” CEO Gavin Jackson added. “It was a distinction investors understood quickly in the first 30 seconds of us talking to them.” Continues... |
Posted at 05/1/2023 22:38 by bamboo2 Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics05 Jan 2023 $30 million convertible note financing co-led by ARCH Venture Partners, Parker Institute for Cancer Immunotherapy, and Westlake Village BioPartners expands investor base to include leading US life science venture capital firms Clinical-stage NG-350A and NG-641 tumor gene therapies demonstrating consistent safety & tolerability profiles, as well as preliminary evidence of clinical activity in Phase 1 studies providing support for planned clinical PoC generation in future expansion cohorts Relaunch represents critical next step in the ongoing corporate transformation which builds on Q3 2022 appointment of Howard Davis, Ph.D., as CEO and Q4 2022 establishment of US offices in Cambridge, Massachusetts CAMBRIDGE, MA (USA) and OXFORD (UK) – January 5, 2023 – Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced a $30 million convertible note financing co-led by a group of leading US life science investors. In addition, the company provided a progress update on its clinical pipeline programs, NG-350A and NG-641, while announcing a relaunch of the company as Akamis Bio building upon its ongoing corporate transformation. In conjunction with the corporate name change, the company has launched a new website at www.akamisbio.com. The $30 million convertible note financing was co-led by new US investors ARCH Venture Partners, the Parker Institute for Cancer Immunotherapy, and Westlake Village BioPartners. It will further fund development activities for the clinical stage NG-350A and NG-641 programs, as well as general corporate purposes. “Over the last several years, we have undergone an incredible transformation as a company, and our new name reinforces this evolution and our focused commitment to oncology drug development. The $30 million financing will enable the continued advancement of our clinical pipeline of T-SIGn® therapeutics and further establishes our US footprint,” said Howard Davis, Ph.D., Chief Executive Officer of Akamis Bio. “As we relaunch the company today, we thank our existing and new investors for their support and shared commitment to leveraging our groundbreaking solid-tumor targeted T-SIGn® therapeutics to turn the tide in the battle against cancer.” Akamis Bio, formerly PsiOxus Therapeutics, was founded and has grown with the support of leading global and European investors including SROne, IP Group, Hambro Perks, Lundbeckfonden, Sedgwick Yard, Mercia Asset Management, and Rosetta Capital Limited. “We are excited to support the talented team at Akamis Bio in their efforts to bring a set of powerful new immuno-oncology therapeutics to people living with cancer,” said Robert Nelsen, Co-founder and Managing Director of ARCH Venture Partners. “We are delighted to partner with Akamis Bio’s existing investors as the company advances its current clinical programs and continues to expand its pipeline of T-SIGn® therapeutics.” Clinical Progress Update – NG-350A & NG-641 Akamis Bio’s T-SIGn® therapeutics are viral vector-based, tumor gene therapies which have demonstrated the ability to specifically home to and replicate within primary and metastatic solid tumor tissue following intravenous delivery. Once at the tumor site, T-SIGn® therapeutics can drive intratumoral expression of multiple immunologically active biomolecules and therapeutic proteins to remodel the tumor microenvironment and trigger robust antitumor immune responses. Akamis Bio’s clinical pipeline of T-SIGn® therapeutics is anchored by two Phase 1 programs: NG-350A, an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody; and NG-641, a stromal-targeted tumor gene therapy driving intratumoral expression of a FAP-CD3 bispecific antibody, CXCL-9, CXCL-10, and interferon alpha. Across more than 200 patients with epithelial-derived solid tumors who have been treated in Akamis Bio’s clinical trials to date, T-SIGn® therapeutics have been well-tolerated and demonstrated a consistent safety profile. In clinical studies, NG-350A and NG-641 have shown promising preliminary evidence of clinical activity including dose-dependent elevation of systemic immune response cytokines and dose-dependent increases in CD8+ immune cell infiltrates within the targeted solid tumor tissue. As the ongoing clinical studies for NG-350A (FORTITUDE and FORTIFY) and NG-641 (STAR, NEBULA, and MOAT) advance in 2023, Akamis Bio will continue to assess safety, tolerability, and preliminary efficacy in both monotherapy and combination (with checkpoint inhibitors) settings, as well as the potential benefits of multiple cycles of T-SIGn® therapeutic dosing. Akamis Bio anticipates the initiation of a set of expansion cohort studies for NG-350A and NG-641 in early 2024 to demonstrate clinical proof-of-concept in patient populations with a single type of epithelial-derived solid tumor. Akamis Bio Corporate Relaunch The company’s new name is derived from “Akamas,” The company’s relaunch builds on the ongoing corporate transformation which has included the Q3 2022 hiring of a new US-based CEO in Howard Davis, Ph.D., as well as the company’s Q4 2022 establishment of its hub of US operations in Kendall Square in Cambridge, Massachusetts. In conjunction with the corporate name change, the company has launched a new website (www.akamisbio.com). About T-SIGn® Akamis Bio’s Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics are chimeric group B adenoviral vector-based, tumor gene therapies which are capable of homing specifically to primary and metastatic solid tumors following intravenous delivery. Once at the tumor site, T-SIGn® therapeutics can drive intratumoral expression of multiple immunologically active biomolecules and therapeutic proteins encoded by the vector to remodel the tumor microenvironment and trigger robust antitumor immune responses. T-SIGn® therapeutics have potential for use in the treatment of solid tumors as monotherapy, as well as in combination with other immuno-oncology agents (e.g., checkpoint inhibitors, antibody drug conjugates, bispecific T-cell engagers, and cell therapies) to enable and/or enhance the efficacy of those modalities in the solid tumor setting. Akamis Bio has an extensive and growing body of clinical experience with T-SIGn® therapeutics with more than 200 patients treated across both the monotherapy setting, as well as in combination with checkpoint inhibitors. Across clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety and tolerability profile, as well as promising preliminary evidence of clinical activity.About Akamis Bio Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis Bio has a growing pipeline of T-SIGn® therapeutics anchored by its two clinical-stage programs, NG-350A (an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody) and NG-641 (a stromal-targeted tumor gene therapy leveraging a viral vector encoding a FAP-CD3 bispecific antibody, CXCL-9, CXCL-10 & interferon alpha). NG-350A and NG-641 are both being investigated in ongoing Phase 1 clinical studies in patients with metastatic or advanced epithelial tumors. In addition to internal pipeline development efforts, Akamis Bio has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI). To learn more, please visit www.akamisbio.com. |
Posted at 04/10/2022 12:30 by bamboo2 15 September 2022FOR RELEASE ON 15(th) September 2022 IP Group plc - Investor presentation IP Group plc (LSE: IPO) ("IP Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, is pleased to announce that it will host an industry-wide event titled 'Technology Trailblazers: Backing Deeptech to 2030 and Beyond' on Wednesday 05 October 2022. The IP Group Deeptech team looks forward to welcoming investors, co-investors, analysts and the wider tech ecosystem for a thought-provoking evening of talks from two of the UK's foremost technology innovators. Dr Tom Carter, decorated innovator and Founder & CEO of multi award-winning technology company Ultraleap Ltd will speak on 'The Metaverse: a playground, classroom or workplace?'. Professor Niki Trigoni, head of the University of Oxford Cyber Physical Systems Group and founder of Navenio Ltd, will speak on the topic of 'Where next for applied AI?'. In 2020 Niki won the KPMG Award for "Best British Tech Pioneer" and in 2022 she won "CTO of the Year" at the UK's Women in IT Awards. These talks will be followed by a short panel discussion comprising the speakers alongside IP Group's Managing Partner for Technology, Dr Mark Reilly. The event will be hybrid (both in person and virtual) and take place from 5.00pm. For further information and to register to attend, please visit the events section of our website: hxxps://www.ipgroupp The online update will be hosted through the Investor Meet Company platform. Questions can be submitted in advance of the event via the Investor Meet Company Platform up to 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: hxxps://www.investor The in-person event will be followed by networking alongside drinks and canapes. No material new information will be released by the Company during the presentation. |
Posted at 16/9/2022 07:51 by bamboo2 FOR RELEASE ON 15(th) September 2022IP Group plc - Investor presentation IP Group plc (LSE: IPO) ("IP Group" or "the Company"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, is pleased to announce that it will host an industry-wide event titled 'Technology Trailblazers: Backing Deeptech to 2030 and Beyond' on Wednesday 05 October 2022. The IP Group Deeptech team looks forward to welcoming investors, co-investors, analysts and the wider tech ecosystem for a thought-provoking evening of talks from two of the UK's foremost technology innovators. Dr Tom Carter, decorated innovator and Founder & CEO of multi award-winning technology company Ultraleap Ltd will speak on 'The Metaverse: a playground, classroom or workplace?'. Professor Niki Trigoni, head of the University of Oxford Cyber Physical Systems Group and founder of Navenio Ltd, will speak on the topic of 'Where next for applied AI?'. In 2020 Niki won the KPMG Award for "Best British Tech Pioneer" and in 2022 she won "CTO of the Year" at the UK's Women in IT Awards. These talks will be followed by a short panel discussion comprising the speakers alongside IP Group's Managing Partner for Technology, Dr Mark Reilly. The event will be hybrid (both in person and virtual) and take place from 5.00pm. For further information and to register to attend, please visit the events section of our website: . The online update will be hosted through the Investor Meet Company platform. Questions can be submitted in advance of the event via the Investor Meet Company Platform up to 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: . Investors who already follow IP Group plc on the Investor Meet Company platform will automatically be invited. The in-person event will be followed by networking alongside drinks and canapes. No material new information will be released by the Company during the presentation. |
Posted at 02/8/2022 07:42 by bamboo2 FOR RELEASE ON 02 August 2022IP Group plc - Portfolio company Hysata completes oversubscribed series A funding round to develop pilot manufacturing facility IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which develops world-changing science and technology businesses across life sciences, technology and cleantech , notes that portfolio company Hysata Pty Ltd ("Hysata" or "the Company") has raised $A42.5m (GBP24.3m*) to help develop a pilot manufacturing facility aimed at delivering the world's lowest cost green hydrogen. Hysata, an Australian electrolyser company developing a completely new type of electrolyser featuring the world's most efficient electrolysis cell, launched last year having spun out of the University of Wollongong. The Hysata electrolyser operates at 95% system efficiency (41.5 kWh/kg), delivering a leap in performance and cost over incumbent technologies, which typically operate at 75% or less. This high efficiency, coupled with the simple approach to mass manufacturing and low supply chain risk puts the company on a path to delivering the world's lowest cost green hydrogen . IP Group committed a total of A$19m (GBP10.9m*) to the funding round (A$9m(GBP5.1m*) from IP Group Australia and A$10m (GBP5.7m*) from our cleantech platform, Kiko Ventures). Following completion, the Group's stake in Hysata is valued at approximately GBP19.0m. IP Group has recorded a net unrealised fair value gain of approximately GBP8.4m. Greg Smith, Chief Executive Officer of IP Group , said: "Hysata has made excellent technical progress with research in Nature Communications, the scientific journal, confirming its efficiency earlier this year and we're delighted to see Hysata attract such strong interest in this round. This is a great example of IP Group's model where our Australian team have worked closely with our cleantech team in the UK to find, fund and support this exciting hydrogen technology." The full release follows below. *GBP equivalent using 1.75 AUD/GBP For more information, please contact: IP Group plc www.ipgroupplc.com +44 (0) 20 7444 0062/+44 (0) Liz Vaughan-Adams, Communications 7967 312125 Charlotte Street Partners David Gaffney +44 (0) 7854 609998 Andrew Wilson +44 (0) 7810 636995 Notes for editors About IP Group IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com . S Green hydrogen company Hysata's Series A funding exceeds $40 million The Clean Energy Finance Corporation, Kiko Ventures, IP Group Australia, Vestas Ventures, and Hostplus are among the top-tier investors supporting Hysata's Capillary-Fed Electrolyser (Sydney, Australia) Tuesday 2 August 2022 Australian company Hysata's world-leading hydrogen electrolyser technology has been supported by renowned global investors, as the organisation closes its oversubscribed Series A funding round of $42.5 million AUD. Virescent Ventures led the funding round on behalf of the Clean Energy Finance Corporation (CEFC) (Aus), with participation from Kiko Ventures (UK), IP Group Australia, Vestas Ventures (Denmark), Hostplus (Aus) and BlueScope (via its ventures arm BlueScopeX (TM) ) (Aus). Assembling such a high profile and high impact list of investors underlines the significance of the transformation that Hysata is bringing to the green hydrogen industry. The Hysata electrolyser operates at 95% system efficiency (41.5 kWh/kg), delivering a giant leap in performance and cost over incumbent technologies, which typically operate at 75% or less. This high efficiency, coupled with the simple approach to mass manufacturing and low supply chain risk puts the company on a path to delivering the world's lowest cost green hydrogen. Funding from the Series A round will be used to grow the Hysata team and develop a pilot manufacturing facility. "Our mission is to redefine the economics of green hydrogen production through our innovative proprietary electrolyser technology. The support of this international syndicate of clean energy practitioners and investors validates our core technology and our approach to scaling and mass manufacture," said Paul Barrett, CEO of Hysata. "Green hydrogen is a vital energy vector on the world's path to net zero, critical to decarbonising the hard-to-abate, yet vital, sectors of our economy such as steelmaking, heavy transport, and the chemical industry. The extensive end use cases for green hydrogen translate to a greater than trillion-dollar market opportunity. "Over the last 12-18 months, Hysata has been interacting with dozens of major customers globally. The impact our efficiency and system simplicity delivers to customers' project economics truly moves the needle. We look forward to continuing to work with our shareholders and customers to bring this much needed technology to market as soon as possible." The CEFC invested $10 million into the Series A funding round, building on its initial $750,000 investment in the early commercial development of Hysata's research. CEFC CEO Ian Learmonth said that backing a company like Hysata and its cutting-edge electrolyser technology is vital in helping to grow Australia's clean technology ecosystem. "The CEFC is proud to continue our support for Hysata, which is set to be a major player in the global electrolyser industry. Green hydrogen will be essential to addressing the hardest to abate sources of emissions, and we're excited to see Australian ingenuity providing the technology solutions that will help this industry reach scale. The CEFC has a strong focus on hydrogen related investments through both our Innovation and Advancing Hydrogen Funds and we are delighted to see Hysata continue to advance hydrogen to help meet future energy needs and reduce emissions in more sectors of the Australian economy," Mr Learmonth said. The CEFC investment is via its specialist Clean Energy Innovation Fund, which is managed by Virescent Ventures. Virescent Ventures Partner Blair Pritchard said: "Hysata continues to make rapid progress and we are pleased to support such an innovative company with an outstanding team. The continued growth of Hysata is an important pointer to the enormous potential of hydrogen to our net zero future." Kiko Ventures' Founding Partner, Robert Trezona, said Hysata has real potential to become a major global clean technology player. "Having assessed scores of electrolyser technologies in my 20 years in cleantech, Hysata's technology stands out as a true breakthrough. The company has redefined the core cell architecture for alkaline electrolysis, producing a practical and scalable solution with game changing efficiency. Hysata has the potential to be a globally significant company in the hydrogen economy and we look forward to supporting its growth, especially here in Europe." Dr Trezona said. IP Group Australia's Managing Director, Michael Molinari, added: "Hysata have assembled a world-class team to bring their revolutionary capillary-fed electrolyser to market. We're proud to have supported the company from before inception at the University of Wollongong to now redefining the economics of green hydrogen with their electrolyser that is set to scale." Todd O'Neill, CEO of Vestas Ventures, said: "As the venture capital arm of the world's leading renewable technology provider, Vestas Ventures foresees great potential in combining wind power with electrolysers for green hydrogen production. We are delighted to have been invited to invest in Hysata. Nurturing disruptive renewable technologies is central to our investment strategy and we look forward to following Hysata's success over the coming years." BlueScopeX(TM) 's General Partner, Michael Quinn, agreed that Hysata's technology could play a significant role in the development of commercially viable hydrogen production. "BlueScopeX(TM) is pleased to be investing in Australian technologies coming out of our local communities, with Hysata being born in the Illawarra. Our industry requires smart, affordable technologies like Hysata's to help progress the broader goal of decarbonisation, and we are excited to be supporting them on their path to commercialisation," he said. S About Hysata Hysata is an Australian electrolyser company which is developing a completely new type of electrolyser, featuring the world's most efficient electrolysis cell coupled with a simplified balance of plant. Electricity makes up most of the cost of green hydrogen and therefore, the most efficient electrolyser will deliver the lowest cost hydrogen. The Hysata founding team comprises electrolyser industry veterans, with deep expertise in the design and scale-up of novel electrolysers. Building on that foundation we are growing a world-class engineering, manufacturing, and commercial team with a footprint on multiple continents. Backed by leading global investors, Hysata is moving rapidly towards manufacturing at the multi-gigawatt scale needed to address climate change. For more information visit www.hysata.com About the CEFC The CEFC has a unique mission to accelerate investment in Australia's transition to net zero emissions. We invest to lead the market, operating with commercial rigour to address some of Australia's toughest emissions challenges. We're working with our co-investors across renewable energy generation and energy storage, as well as agriculture, infrastructure, property, transport and waste. Through the Advancing Hydrogen Fund, we're supporting the growth of a clean, innovative, safe and competitive hydrogen industry. And as Australia's largest dedicated cleantech investor, we continue to back cleantech entrepreneurs through the Clean Energy Innovation Fund. With $10 billion to invest on behalf of the Australian Government, we work to deliver a positive return for taxpayers across our portfolio. About Virescent Ventures Virescent Ventures was born out of the Clean Energy Innovation Fund , part of the Clean Energy Finance Corporation . Virescent invests in pre-seed to late-stage growth capital, and makes investments that address the largest, hardest to abate sources of emissions. For more information visit www.virescent.vc About Kiko Ventures Kiko Ventures is a US$450m venture investor that supports transformative climate tech and is the world's first evergreen cleantech VC. Launched in 2022 by the FTSE 250 listed investment firm IP Group plc, Kiko Ventures was founded to create new possibilities for a regenerative future. It is a highly flexible investment platform using IP Group's balance sheet capital and aims to be a long-term partner to leading climate tech innovators. For more information visit www.kiko.vc About IP Group Australia IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech. The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc. In Australia and New Zealand, IP Group works in close partnership with the Go8 Universities and the University of Auckland to identify ground-breaking technologies rooted in hard science, which have the most promising commercial potential. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information visit www.ipgroupanz.com About Vestas Ventures Vestas Ventures is the corporate venture capital arm of Vestas Wind Systems, the world's leading renewable technology provider. Vestas Ventures invests in startups that support Vestas' vision to be the global leader in sustainable energy solutions. For more information visit www.vestas.com/ventu About Hostplus Hostplus has grown to be one of the largest industry super funds in Australia. With over 1.5 million members, more than 269,000 employers and $86.6 billion in funds under management (as at 30 June 2022), our scale and ongoing growth allows for low member costs and a broad range of investment opportunities. For more information visit www.hostplus.com.au About BlueScopeX(TM) BlueScope is one of the world's leading manufacturers steel coated products and commercial steel buildings. BlueScope is publicly listed on the Australian Stock Exchange, with an approximate market cap of $10b and >14,000 employees globally. BlueScopeXTM is the ventures arm of BlueScope, dedicated to investing in and accelerating start-ups and businesses developing technologies and solutions in the decarbonisation space, and efficiency improvements in the built environment. For more information visit www.bluescope.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
